Remove ACE Inhibitor Remove Diabetes Remove Outpatient
article thumbnail

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”

article thumbnail

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

SGLT-2 inhibitors were initially approved to treat Type 2 diabetes by lowering blood sugar. About 32% had Type 2 diabetes. This finding is completely consistent in both direction and magnitude with other studies of SGLT-2 inhibitors in populations with diabetes and chronic kidney disease.”